The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity.

BACKGROUND There are difficulties with the diagnosis of serotonin toxicity, particularly with the use of Sternbach's criteria. AIM To improve the criteria for diagnosing clinically significant serotonin toxicity. DESIGN Retrospective analysis of prospectively collected data METHODS We studied all patients admitted to the Hunter Area Toxicology Service (HATS) following an overdose of a serotonergic drug from January 1987 to November 2002 (n = 2222). Main outcomes were: diagnosis of serotonin toxicity by a clinical toxicologist, fulfillment of Sternbach's criteria and treatment with a serotonin receptor (5-HT(2A)) antagonist. A learning dataset of 473 selective serotonin reuptake inhibitor (SSRI)-alone overdoses was used to determine individual clinical features predictive of serotonin toxicity by univariate analysis. Decision rules using CART analysis were developed, and tested on the dataset of all serotonergic overdose admissions. RESULTS Numerous clinical features were associated with serotonin toxicity, but only clonus (inducible, spontaneous or ocular), agitation, diaphoresis, tremor and hyperreflexia were needed for accurate prediction of serotonin toxicity as diagnosed by a clinical toxicologist. Although the learning dataset did not include patients with life-threatening serotonin toxicity, hypertonicity and maximum temperature > 38 degrees C were universal in such patients; these features were therefore added. Using these seven clinical features, decision rules (the Hunter Serotonin Toxicity Criteria) were developed. These new criteria were simpler, more sensitive (84% vs. 75%) and more specific (97% vs. 96%) than Sternbach's criteria. DISCUSSION These redefined criteria for serotonin toxicity should be more sensitive to serotonin toxicity and less likely to yield false positives.

[1]  I. Whyte,et al.  Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity. , 2003, British journal of clinical pharmacology.

[2]  G. Isbister,et al.  Olanzapine and serotonin toxicity , 2003, Psychiatry and clinical neurosciences.

[3]  B. Katirji,et al.  Mirtazapine-induced serotonin syndrome. , 2003, Clinical neuropharmacology.

[4]  Shailesh Kumar,et al.  Can olanzapine be implicated in causing serotonin syndrome? , 2002, Psychiatry and clinical neurosciences.

[5]  H. S. Duggal,et al.  Serotonin syndrome and atypical antipsychotics. , 2002, The American journal of psychiatry.

[6]  G. Huether,et al.  Stress regulation and self-mutilation. , 2002, The American journal of psychiatry.

[7]  I. Whyte,et al.  Serotonin toxicity with therapeutic doses of dexamphetamine and venlafaxine , 2002, The Medical journal of Australia.

[8]  B. Currie,et al.  Occupational infection with herpes simplex virus type 1 after a needlestick injury , 2002, The Medical journal of Australia.

[9]  Ian M Whyte,et al.  Data Collection in Clinical Toxicology: Are There Too Many Variables?* , 2002, Journal of toxicology. Clinical toxicology.

[10]  I. Whyte,et al.  Comment: Serotonin Syndrome Induced by Fluvoxamine and Mirtazapine , 2001, The Annals of pharmacotherapy.

[11]  M. Malone,et al.  Serotonin Syndrome Induced by Fluvoxamine and Mirtazapine , 2001, The Annals of pharmacotherapy.

[12]  A. Dawson,et al.  Comment: Serotonin Syndrome and 5-HT2A Antagonism , 2001, The Annals of pharmacotherapy.

[13]  I. Whyte,et al.  Citalopram Overdose, Serotonin Toxicity, or Neuroleptic Malignant Syndrome? , 2001, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[14]  M. Boyle,et al.  Moving from the Clinic to the Community: The Alone Mothers Together Program , 2001, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[15]  B. Strom Comment: Comparison of FDA Reports of Patient Deaths Associated with Sildenafil and Injectable Alprostadil , 2001, The Annals of pharmacotherapy.

[16]  E. Richelson,et al.  Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. , 2000, Life sciences.

[17]  S. Dursun,et al.  An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria. , 2000, Medical hypotheses.

[18]  G. Littlejohn,et al.  Knee osteoarthritis: Current therapeutic strategies , 1999 .

[19]  I. Whyte,et al.  Preformatted admission charts for poisoning admissions facilitate clinical assessment and research. , 1999, Annals of emergency medicine.

[20]  J. Fraser,et al.  Life-threatening fluvoxamine overdose in a 4-year-old child , 1999, Intensive Care Medicine.

[21]  P. Gillman The serotonin syndrome and its treatment , 1999, Journal of psychopharmacology.

[22]  P. Gillman Serotonin syndrome: history and risk , 1998, Fundamental & clinical pharmacology.

[23]  D. Baldwin,et al.  Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. , 1997, Journal of clinical psychopharmacology.

[24]  K. Ilett,et al.  Fatal Serotonin Syndrome following a Combined Overdose of Moclobemide, Clomipramine and Fluoxetine , 1995, Anaesthesia and intensive care.

[25]  K. Sporer The Serotonin Syndrome , 1995, Drug safety.

[26]  I. Whyte,et al.  Self‐poisoning in Newcastle, 1987‐1992 , 1995, The Medical journal of Australia.

[27]  H. Sternbach The serotonin syndrome. , 1991, The American journal of psychiatry.

[28]  Leo Breiman,et al.  Classification and Regression Trees , 1984 .

[29]  T. Insel,et al.  Possible development of the serotonin syndrome in man. , 1982, The American journal of psychiatry.

[30]  R. Baloh,et al.  Myoclonus and ocular oscillations induced by L‐tryptophan , 1982, Annals of neurology.

[31]  A. Sjoerdsma,et al.  Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor , 1960, Neurology.

[32]  M. Rapport,et al.  Serum vasoconstrictor, serotonin; isolation and characterization. , 1948, The Journal of biological chemistry.

[33]  Jürgen Gallinat,et al.  The serotonin syndrome scale: first results on validity , 1998, European Archives of Psychiatry and Clinical Neuroscience.